Application of a Prediction Model for Directing Antibiotic Use in the Treatment of Urinary Tract Infection in an Ambulatory Setting
NCT ID: NCT06976125
Last Updated: 2026-01-27
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
NOT_YET_RECRUITING
NA
47 participants
INTERVENTIONAL
2026-03-01
2026-06-01
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
In the emergency department (ED), healthcare providers rely on symptoms, along with a urine analysis and a urine culture to diagnose a UTI. A urine analysis involves taking a sample of urine and analyzing different factors like color, acidity, presence of blood cells, presence of bacteria. An abnormal urine analysis increases the likelihood that patients might have a UTI, but it does not confirm it. A positive urine analysis will lead to provider's sending a sample of urine for a urine culture. A urine culture is used to grow whatever bacteria is in the collected urine. If growth is seen on the culture, then this confirms a patient has a UTI. This also specifies which bacteria grew on the culture. The lab can also take it a step further and do an antibiotic test to check which antibiotic the bacteria is sensitive to.
When a urine analysis comes back abnormal in an ER setting, patients are prescribed an antibiotic before the culture and antibiotic sensitivity tests come back. If a patients condition is not critical, they will be discharged home before the culture results come back. If the culture comes back positive, the pharmacists will evaluate the culture and antibiotic sensitivity tests, then call patients to inform them whether they are taking a suitable antibiotic.
This study aims to decrease the unnecessary use of antibiotics because this contributes to antibiotic resistance which is considered a global public health issue. Antibiotic resistance occurs when bacteria develop the ability to withstand certain antibiotics that used to be effective against them, which makes it difficult to treat the infection. One of the factors that increase the risk of antibiotic resistance is the overuse of antibiotics.
In this study, investigators will be incorporating a prediction model and a negative callback system to decrease unnecessary antibiotic use.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Diagnosis of Subclinical Urinary Tract Infections Using Advanced Microbiome Survey Techniques in High Risk Trauma Patients
NCT01834391
Implementation Study With Decision Support Based on Data
NCT04408976
Diagnosis and Treatment of Urinary Tract Infection Using DNA Polymerase Chain Reaction Versus Urine Culture
NCT06808451
Identification of Predictive Blood Biomarkers of Recurrent Urinary Tract Infections
NCT03819712
Intravesical Gentamicin to Prevent Recurrent UTI
NCT06332781
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NA
SINGLE_GROUP
PREVENTION
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Presenting to ER for Urinary Tract Infection (UTI)
Patients presenting to the a UH ER location for UTI symptoms.
Decision Aid-prediction model
ER physician will input the necessary de-identified data into the decision aid application.
The decision aid determines if the patient has a high or low likelihood of having a positive urine culture. The patient with high likelihood of positive culture, will be prescribed empiric antibiotics per the UH guidelines for treating UTI in the ambulatory setting. Patients with a low likelihood of having a positive culture, will be discharged without antibiotics.
Study team members will give the patient a handout describing what will happen in the event of a positive or negative culture.
The culture call-back team, consisting of clinical pharmacists, will be notified.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Decision Aid-prediction model
ER physician will input the necessary de-identified data into the decision aid application.
The decision aid determines if the patient has a high or low likelihood of having a positive urine culture. The patient with high likelihood of positive culture, will be prescribed empiric antibiotics per the UH guidelines for treating UTI in the ambulatory setting. Patients with a low likelihood of having a positive culture, will be discharged without antibiotics.
Study team members will give the patient a handout describing what will happen in the event of a positive or negative culture.
The culture call-back team, consisting of clinical pharmacists, will be notified.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Age \>18 years old
* Discharged from the hospital after ER visit
* Discharge ICD code consistent with a UTI diagnosis
* Antibiotic prescribed for UTI at the time of discharge
Exclusion Criteria
* Necessity for chronic bladder catheterization or discharge with a urinary catheter
* Patients who have an Emergency Severity Index (ESI) of 1 and 2
* Patients who verbalize to the study team member that their pain is a 6 or higher
* Patient set to be transferred to inpatient care
* History of bladder augmentation
* Pregnancy (this will be confirmed with a negative pregnancy test which is ordered in the ER)
18 Years
FEMALE
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
University Hospitals Cleveland Medical Center
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
David Sheyn
Physician
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
David Sheyn, MD
Role: PRINCIPAL_INVESTIGATOR
University Hospitals Cleveland Medical Center
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
University Hospitals Cleveland Medical Center
Cleveland, Ohio, United States
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
STUDY20250812
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.